Discovery, Distribution, and Receptors
======================================

The endogenous dipeptide [L]{.smallcaps}-tyrosine-[L]{.smallcaps}-arginine (YR) was first isolated from bovine brain in 1979 and found later on in other mammals' brains and in human cerebrospinal fluid (CSF) ([@B85]; [@B91]; [@B54]; [@B73]). The dipeptide with endorphin-like properties discovered in Kyoto was named kyotorphin (KTP) ([@B84]).

Kyotorphin can be formed in the brain by two pathways: (i) from precursor proteins degradation either by membrane-bound aminopeptidase or cytosolic Ca^2+^ activated protease ([@B90]; [@B101]; [@B4]); and/or (ii) from its precursor [L]{.smallcaps}-amino acids, tyrosine and arginine, in a reaction catalyzed by KTP synthetase dependent of ATP and Mg^2+^ ([@B92]). This pathway produces three--fourfold more KTP than the one formed by precursor proteins degradation ([@B92]).

KTP synthetase distribution correlates closely with KTP levels in the rat brain ([@B92]). Its enzymatic activity was also detected in rat adrenal glands and spinal cord ([@B43]).

KTP is unevenly distributed over the brain. Lower brain stem regions, such as midbrain, pons, medulla oblongata and dorsal part of spinal cord are KTP-rich regions. These regions are sensitive to morphine and/or electrical stimulation-induced analgesia. However, 50% of total KTP brain's content is concentrated in cerebral cortex, an area with low content of opioid receptors and enkephalinases ([@B91]). Lower KTP contents can be found in striatum, hippocampus, hypothalamus, thalamus, and cerebellum ([@B91]). The regional distribution of KTP supports the idea that KTP might have non-opioid actions.

Subcellular fractioning revealed KTP is enriched in synaptosomal fraction. Synaptosomes preloaded with KTP were able to release the dipeptide in a Ca^2+^ dependent manner upon depolarizing stimuli and it seems KTP can be recaptured again by synaptosomes in a Na^+^, temperature and energy-dependent manner. These data support the idea that KTP plays a role as neurotransmitter/neuromodulator ([@B89],[@B94]).

Specific binding-assays using radioactive KTP suggest the presence of high affinity and low affinity receptors in the brain. The mechanism triggered by the binding of KTP to KTPr is mediated through protein *G*~i~ and phospholipase C (PLC) system that induces Ca^2+^ influx ([@B93]). Thus, a nerve impulse is generated, ultimately leading to analgesia. The synthetic dipeptide [L]{.smallcaps}-leucine-[L]{.smallcaps}-arginine (LR) also binds KTPr with a great affinity but no effect, thereby constituting a potent antagonist ([@B93]).

Interestingly, extremely low doses of KTP (femtomolar range) and more stable analogs (atomolar range) administered peripherally elicit nociceptive responses due to the release of substance P (SP) by nociceptor endings of primary afferent neurons. The authors speculate that the mechanism involved in such opposite responses (antinociceptive vs. nociceptive) might be mediated by different G proteins depending on KTP dosage, having a differential effect on PLC activation ([@B39]; [@B87]).

The putative KTPr has not been identified yet. Despite many papers refer to "the KTPr" ([@B91], [@B94], [@B93], [@B88]; [@B87]), it is not clear whether the receptor is specific or formed by μ- and δ-opioid receptors oligomerization ([@B51]). From previous studies it is known that KTPr binding pocket must be different from opioid receptors ([@B85]; [@B60]; [@B87]), but conformational studies on KTP suggested they should be structurally similar ([@B51]).

Metabolism and Clearance
========================

PEPT2 Transporter
-----------------

Neuropeptides are released in the brain to exert their function and thereafter they are cleared either by extracellular peptidases and/or removed from extracellular fluid by specific transporters. Both processes have shown to be equally important in KTP clearance ([@B99]).

[@B30] were the first to report an interaction between KTP and the high-affinity transporter PEPT2, albeit in an indirect way, evaluating competitive inhibition of glycylsarcosine (GlySar) in rat synaptosomes. Later, KTP uptake by PEPT2 was demonstrated in a more direct way, measuring the peptide-induced inward currents ([@B86]).

PEPT2 is high-affinity and low capacity transporter which rely on a pH gradient between extracellular and intracellular compartments to transport di- and tri-peptides. This transporter is expressed in kidney, retina and brain ([@B47]; [@B9]). Hybridization studies showed PEPT2 is expressed in astrocytes and ependymal cells throughout the brain, and also in epithelial cells of choroid plexus ([@B9]; [@B23]). Astrocytes are essential in the control of neuronal activity and synaptic neurotransmission ([@B6]), and several peptidases are known to be expressed on their extracellular membrane ([@B9]). Therefore, PEPT2 function in astrocytes might be linked to the removal of neuropeptide fragments and small biologically active peptides from extracellular fluid, such as KTP and carnosine ([@B9]). In choroid plexus, the transporter is specifically located in the apical membrane, suggesting a role in the efflux of peptides from CSF ([@B78]). In addition, PEPT2 null mice showed enhanced antinociceptive response to intracerebroventricular (i.c.v.) administered KTP ([@B42]). Transport of peptides from blood to CNS via PEPT2 is unlikely since this transporter is not present at blood--brain barrier (BBB) ([@B9]).

KTP-Degrading Aminopeptidases
-----------------------------

Kyotorphin-degrading aminopeptidase activity was reported in brain homogenate ([@B90]), lung and skin from rats ([@B55]). KTPase activity was inhibited by bestatin, but not puromycin, a potent inhibitor of soluble aminopeptidases ([@B90]). [@B3] and [@B2] identified two distinct KTPases in soluble fraction of rat brain. KTPase I is responsible for 95% of KTP-degrading activity, while KTPase II, which showed to be an enkephalin aminopeptidase, contributes only to 5% of KTP degradation.

Moreover, other authors found two dipeptide-cleaving enzymes associated to synaptic membranes ([@B55]). Both enzymes are inhibited by bestatin, but they can be distinguished based on their differential sensitivity to amastatin ([@B55]). Although KTPase I, described in [@B2] presents similar characteristics to the KTP-degrading enzyme found by [@B55], it is not clear if they are identical ([@B4]).

Mechanism of Action
===================

The first experiments done by [@B85] revealed an analgesic activity of KTP 4.2 fold more potent than met-enkephalins, when injected intracisternally; an effect that was reversed by naloxone. Although naloxone is an opioid antagonist, studies demonstrated KTP itself does not bind to opioid receptors, but has rather an indirect action mediated by met-enkephalin and β-endorphin, which activate δ- and/or μ-opioid receptors ([@B85]; [@B60]; [@B63]). Other authors confirmed KTP-induced met-enkephalin release from guinea pig and rat brain slices ([@B77]; [@B83]; [@B41]). In addition, there are evidences that KTP can inhibit some enkephalinases. This implies that met-enkephalins would be more protected from enzymatic degradation resulting in a relatively long-lasting analgesia ([@B85]; [@B35]).

In patients with persistent pain, [L]{.smallcaps}-Arg intravenously administered induced analgesia and this action was antagonized by naloxone ([@B81]; [@B82]; [@B34]). It has been postulated that [L]{.smallcaps}-Arg can facilitate KTP synthesis in the brain, enhancing met-enkephalin release, which in turn activate δ- and/or μ-opioid receptors resulting in antinociception ([@B45]).

Alternatively, [L]{.smallcaps}-Arg is a well-known substrate for NOS. NOS and soluble guanylyl cyclase inhibitors administered i.c.v. caused antinociception. These findings led [@B44], [@B45]) to conclude that [L]{.smallcaps}-Arg plays a dual role in nociceptive processing. In this case, NO-cyclic guanosine monophosphate (cGMP) pathway seems to be involved in nociceptive promotion in the CNS.

Kyotorphin-synthetase activity was detected outside the central nervous system (CNS), in adrenal gland, suggesting that KTP might have a role in peripheral system ([@B43]). In accordance, a study conducted in brown fat cell culture system showed KTP inhibited cell proliferation induced by noradrenaline. This indicates that these cells and probably other tissues in the periphery contain receptors for KTP ([@B13]). In order to evaluate if KTP analgesic effect in the periphery was mediated by opioid receptors, a peripheral pain reflex test was conducted in mouse. Results showed the mechanism was mediated via KTPr but independent of opioid receptors, since naloxone was unable to prevent KTP analgesic effect ([@B38]). The mechanism of action of KTP still not clear and some data are contradictory. However, there seems to exist two distinct pathways leading to analgesia, one mediated by opioids and other opioid-independent.

KTPwas clustered in classes according to regular intervals of amplitude of 100 pg/mL Beyond Analgesia
=====================================================================================================

Physiological Effects
---------------------

In addition to the extensively studied analgesic effect, KTP gathers a wide spectrum of biological activities ([@B25]). Published papers have explored KTP role as antiepileptic ([@B32]), thermoregulator ([@B71]), anti-hibernation regulator ([@B37]) and stress ([@B80]) and behavior ([@B46]) modulators.

Kyotorphin is present at moderate concentrations in the hypothalamus ([@B91]), a structure with an important role in thermoregulation and stress. Naloxone-irreversible hypothermia was induced in mice, at room temperature, after i.c.v. administration of KTP and a more stable analog. However, thyrotropin (TRH) prevented this effect, suggesting the mechanism of KTP thermoregulation in the brain might involve the TRH neuronal system instead of opioid receptors ([@B71]). Regarding stress, high doses of KTP injected i.c.v. presumably activates the sympathetic nervous system, inducing a release of oxytocin (OT), a stress-hormone in rodents, concomitantly with elevating blood pressure and glucose plasma levels, but not vasopressin ([@B80]).

Behavioral studies in rats and goldfish showed KTP reduced exploratory behavior mediated probably by the monoaminergic brain systems ([@B46]).

KTP as a Promising Biomarker in Alzheimer's Disease
---------------------------------------------------

Recent estimates indicate 35.6 million people worldwide affected by dementia, a number that is expected to nearly double every 20 years ([@B97]). Alzheimer's Disease (AD) is the most prevalent form of dementia in later life. It is clinically characterized by a progressive deterioration of memory, orientation, language, learning capacity, emotional stability, motor skills, and ultimately self-care, causing social and occupational disability. Unfortunately, no effective cure is available and current treatment strategies only provide symptomatic relief without halting nor reversing disease progression.

There is an increased need for AD biomarkers to improve early detection, accurate diagnosis, and accelerate drug development in this field ([@B29]; [@B33]). In medicine, a biomarker is generally defined as a molecule or any other tangible parameter that serves as an indicator of biological or pathogenic processes that can be used to evaluate disease risk or prognosis, and to monitor therapeutic interventions ([@B33]). Decreased CSF levels of β-amyloid peptides (Aβ~40~, Aβ~42~) combined with increased levels of total tau and phosphorylated tau proteins, have diagnostic value in AD ([@B29]; [@B33]), for instance.

Although chronic pain is also highly prevalent in AD patients ([@B59]), its proper evaluation and treatment is a clinical and ethical challenge. It may seem strange because AD patients consume fewer analgesics than other patient groups, making the false impression that they may feel less pain. However, processing and perception of pain are not diminished in AD ([@B18]). In those patients, pain underestimation relates with their limited capacity of verbally expressing their pain or discomfort, worsening as the dementia progresses ([@B59]). Recent evidence suggest that chronic pain contributes to the course of neurodegenerative events as an additional injury to the nervous system ([@B12]). Cognitive impairment and limited communication in AD patients leads to underreported pain, which in turn leads to undertreatment. By failing to receive adequate pain treatment, structural and irreversible changes may occur in the nervous system, aggravating AD pathophysiology which in turn contributes to chronic pain, maintaining a vicious cycle.

The benefits of finding a particular AD biomarker involved in the overlapping mechanisms of nociception and neurodegeneration that can be used in the clinics alongside with the existing ones ([@B29]; [@B33]) are obvious: (a) possibility to evaluate pain, regardless the level of cognitive impairment of the patient; (b) a biomarker that is itself a promising strategy for pharmaceutical development.

Our recent clinical studies showed a link between pain, AD and KTP in humans. In fact, we observe that pain was underestimated in AD patients ([@B72]) and KTP has decreased levels in the CSF of AD patients with moderate cognitive impairment ([@B73]). Several other neuropeptides have been identified as diminished in AD ([@B62]; [@B5]). Lower levels of an analgesic molecule such as KTP may probably explain why AD patients are believed to have a higher incidence of hidden chronic pain; in agreement, [@B54] have shown that CSF KTP levels decrease in chronic pain conditions.

Owing to the estimated low concentration of KTP in the human CSF (10^-9^ M) ([@B54]) we had to resort to electrospray ionization tandem mass spectrometry (ESI -- MS/MS) ([@B73]). The decreased levels of KTP in AD samples correlate with a disease-specific atrophy of some brain regions meaning damage and loss of neuronal cells, which possibly results in less KTP being produced and its CSF concentration naturally falling in those patients (**Figure [1](#F1){ref-type="fig"}**). Moreover, we also found an inverse correlation between levels of KTP and of phosphorylated-tau protein (p-tau) (**Figure [2](#F2){ref-type="fig"}**) ([@B73]). CSF p-tau reflects the phosphorylation state of tau and the formation of cortical neurofibrillary tangles in the brain ([@B29]). As the disease progresses, more neuronal cells are destroyed, p-tau is released and KTP production is impaired (**Figure [1](#F1){ref-type="fig"}**). These decreased levels of KTP in the brain will probably contribute to a decreased NOS activity (see Mechanism of Action) causing a NO deficit to such a degree that will further promote the neurodegenerative events characteristic of AD. Disruption of NO homeostasis is known to hasten the development of AD ([@B22]).

![**Clinical implications of reduced KTP levels in cerebrospinal fluid (CSF) of Alzheimer disease (AD) patients ([@B73])**.](fphar-07-00530-g001){#F1}

![**Phosphorylated-tau (p-Tau) levels dependence on KTP concentration both in AD (red) and normal group (white).** **(A)** Complete data set with individual values (linear regression line plotted as a guide to the eye). **(B)** The data set presented in **(A)** was clustered in classes according to regular intervals of amplitude of 100 pg/mL of p-tau concentration and averaged for KTP concentration (error bars: standard error). The average KTP value of all classes was compared to control (^∗^*p* \< 0.04, ^∗∗^*p* \< 0.0075, ^∗∗∗^*p* \< 0.0006) or the 100- to 200-pg/mL p-tau class (^\#^*p* \< 0.04, ^\#\#^*p* \< 0.0046) using the one-way ANOVA with Dunnett's post-test ([@B73]).](fphar-07-00530-g002){#F2}

Limited Pharmacological Potential of KTP
========================================

The majority of studies on KTP following its discovery aimed to unravel the mechanism of action and to evaluate the analgesic effect of this dipeptide. Although the mechanism of action remains an unsolved issue, direct administration of KTP and some analogs peptides into different parts of CNS showed very promising results regarding analgesia ([@B100]; [@B70]; [@B95]; [@B96]). Hereupon, several groups tested the effects following systemic administration (intraperitoneal i.p., intravenous i.v. and oral) but the results have been disappointing. KTP showed only a brief analgesic activity at a high dose of 200 mg/Kg when administered systemically to rodents ([@B17]).

Blood--brain barrier constitutes the major obstacle to systemically administered drugs to reach CNS due to the tight junctions that link endothelial cells in the brain capillaries and scarcity of receptors. Less than 2% of the drugs developed to treat CNS disorders cross BBB ([@B56]). Even some small lipophilic molecules that succeed to diffuse through BBB and penetrate into the brain can be exported back to blood stream by efflux pumps, such as *P*-glycoproteins. In addition, several lytic proteins located in the brain capillary endothelial cells surface form an enzymatic barrier to bioactive peptides from blood.

Obviously, some essential molecules, such as amino acids, hexoses and neuropeptides, which do not fulfill the criteria to diffuse passively through BBB need to reach the brain. Therefore there are specific carriers that mediate their transport. Larger molecules, such as proteins (e.g., insulin and transferrin) are transported by saturable transport systems. On the other hand, positively charged molecules (e.g., histones and cationized albumin) use an adsorptive-mediated endocytosis mechanism to enter the brain ([@B1]).

At first it was thought KTP inability to cross BBB was related to low affinity of the peptide to lipid membrane ([@B17]). More recently the hypothesis that KTP can be pumped out by specific transporters has been raised ([@B42]; [@B74],[@B75]).

Development of New KTP Derivatives
==================================

Kyotorphin pharmacological potential is limited probably due to its inability to cross BBB and/or susceptibility to enzymatic degradation. In order to overcome these issues while preserving effectiveness as analgesic, several groups including ours have worked in different strategies to modify the original peptide. Some of these strategies deal with (i) chirality ([@B68]; [@B48]), (ii) use of unnatural amino acids and substitution of peptide bonds ([@B26]; [@B75]), (iii) conjugation with lipophilic groups ([@B17]; [@B96]; [@B49]; [@B64]; [@B75]), (iv) cationicity improvement ([@B63]).

Interestingly, some liphophilic groups added to KTP have by themselves a biological action associated. For instance, [@B96] synthesized two distinct KTP derivatives covalently linked to steroids, hydrocortisone (hydrocortisone-KTP) or estrone (estrone-KTP) (**Figure [3](#F3){ref-type="fig"}**). Unlike KTP, hydrocortisone-KTP and estrone-KTP exhibited good analgesia in the tail-flick test after i.p. administration. These derivatives showed improved pharmacokinetics and pharmacodynamics. Moreover, the researchers suggested that the steroids might be enhancing the KTP effect by increasing the number of its receptors ([@B96]).

![**Chemical structure of KTP derivatives**.](fphar-07-00530-g003){#F3}

We have extensively studied the analgesic effect of the derivative KTP-NH~2~, which differs from the original peptide by substitution of the carboxylic acid for an amide (**Figure [3](#F3){ref-type="fig"}**). At physiological pH, this simple chemical modification causes an increase of the net charge of the peptide from +1 to +2. KTP-NH~2~ was tested in acute, sustained and chronic inflammatory and neuropathic pain models following systemic administration (i.p. and oral). At a dosage of 32.3 mg.kg^-1^, KTP-NH~2~ (i.p.) showed an effect comparable to morphine at 5 mg.kg^-1^ in acute pain animal models, meaning the equi-effective dose of KTP-NH~2~ was about fivefold that of morphine. Oral administration required higher dosages to be effective. In chronic pain animal models antinociception induced by KTP-NH~2~ was observed only after a week of daily treatment with 32.3 mg.kg^-1^. In addition, KTP-NH~2~ did not develop resistance unlike morphine, neither jeopardized blood pressure or motor capacity. Accordingly, the peptide showed low affinity to opioid receptors ([@B63]).

Other interesting derivatives are IbKTP and IbKTP-NH~2~, which were designed by us to include in their structure a group corresponding to a lipophilic, analgesic and safe non-steroidal anti-inflammatory drug (NSAID), ibuprofen (Ib), covalently linked to the N-terminal of KTP or KTP-NH~2~, respectively (**Figure [3](#F3){ref-type="fig"}**) ([@B64]). In the clinics, combination of different pain killers have been successfully used, e.g., Vicoprofen^®^ (hydrocodone + Ib). Results in acute and chronic pain models showed that both IbKTP and IbKTP-NH~2~, but mainly IbKTP-NH~2~, improved analgesia after systemic administration ([@B64]).

Recently, eight novel derivatives from KTP and KTP-NH~2~ were synthesized by addition of individual groups at the N-terminus, namely small carbon chains, tert-butyloxycarbonyl (Boc), aminobutyric acid (GABA) or by substitution of the tyrosil residue for an indole moiety. In some cases the peptide bond was substituted by a urea-like bond. The addition of Boc and indolyl groups, but not small carbon chains, increased significantly relative permeability (P~R~) while the peptidomimetics which had the peptide bond substituted by an urea-like bond seemed more resistant to peptidases ([@B75]). Boc-uKTP-NH~2~ and Ind-KTP-NH~2~ (**Figure [3](#F3){ref-type="fig"}**) were the most promising derivatives, showing a prolonged analgesic effect correlated with higher membrane permeability (**Figure [4](#F4){ref-type="fig"}**). These two derivatives successfully combined lipophilicity and resistance to enzymatic degradation ([@B75]). Still, some derivatives with lower permeability, such as KTP-NH~2~, have previously demonstrated good analgesic efficacy ([@B63]). These results suggest that this particular derivative might have specific transporters to translocate BBB ([@B75]).

![**Correlation between the analgesic efficacy and the relative permeability of KTP derivatives ([@B75])**.](fphar-07-00530-g004){#F4}

Other groups studied other interesting derivatives of KTP, namely a glucose-conjugated KTP and cyclic KTP (**Figure [3](#F3){ref-type="fig"}**) ([@B52]). Glucose-mediated drug delivery has been a strategy successfully applied to drugs whose final target is in the CNS \[for review see ([@B76])\]. N-terminal conjugation of p-amino phenyl β-glucoside and C-terminal conjugation of Boc to KTP (Boc-KTP-pAPβglc) (**Figure [3](#F3){ref-type="fig"}**) enhanced absorption and clearance in the rat intestine and cyclization protected the peptide from proteolytic attack, thereby enhancing enzymatic stability. Cyclic-KTP is suggested as a good analgesic drug candidate to be delivered orally ([@B52]).

Advantageous Alternatives over Current Opioids
----------------------------------------------

Opium and its alkaloids (e.g., morphine) have been used for centuries as the most powerful centrally acting compounds for the relief of severe acute and chronic pain. However, they also trigger some side-effects such as nausea, constipation, respiratory depression, urinary retention, clouding of consciousness, motor disturbances, tolerance and addiction, which often hamper their widespread use in clinical practice ([@B28]). Prolonged admininstration of opioids results in tolerance liability that leads to dose escalation, contributing to an increased incidence and severity of all side-effects. This can lead to discontinued use of the pain medication compromising the quality of life for patients. Thus, the discovery and/or development of potent analgesics that result in effective analgesia with fewer side-effects is greatly needed; and this has long been the holy grail of opioid research ([@B79]; [@B20]). In recent years, different approaches have been explored to design and synthesize analogs of naturally occurring opioid peptides (i.e., dermorphin, endomorphins, and enkephalins) as potential substitutes of exogenous opioids for pain relief ([@B31]; [@B40]; [@B65]; [@B58]). Other alternative strategies targeting opioid-receptor have been addressed ([@B79]; [@B65]).

KTP-NH~2~ and IbKTP--NH~2~ exhibited analgesic activity comparable to morphine and lower tolerance ([@B63],[@B64]). Additionally, no evidences of *in vitro* cytotoxicity or hepatic lesions were detected at effective doses ([@B63]). Aiming to validate the pharmaceutical potential of these KTP derivatives as alternative to opioids, further *in vivo* studies were conducted. Hence, for a more detailed pharmacological profiling, both derivatives were studied regarding their side-effects and compared with two clinically relevant opioids, morphine and tramadol ([@B66]). Particular attention was given to the common opioid-induced side-effects namely on locomotion, micturition, gastrointestinal, and cardiovascular functions ([@B8]). For comparison purposes, morphine and tramadol were selected because morphine remains the gold standard in analgesia ([@B61]) while tramadol displays a safer side-effect profile than morphine ([@B24]). In the experimental paradigm, male rats were i.p. injected with a single dose of KTP-NH~2~ (32.3 mg.kg^-1^) or IbKTP-NH~2~ (24.2 mg.kg^-1^) or morphine (5 mg.kg^-1^) or tramadol (10 mg.kg^-1^) before the behavioral/metabolic testing. Doses of KTP derivatives, morphine and tramadol were chosen for inducing comparable analgesia levels in rats ([@B66]).

Our findings clearly showed that both KTP-derivatives do not cause constipation, in contrast to morphine, and do not induce changes in blood pressure, or in water and food intake, in contrast to tramadol. Despite the fact that KTP--NH~2~ (like tramadol) lowered urine volume this seems to be a minor physiological effect caused by this derivative as no major urinary retention occurred (i.e., increased blood pressure was not observed), and may be exploited as a positive effect in cases of micturition disturbances, i.e., detrusor overactivity. IbKTP-NH~2~ only caused a mild motor impairment that was, however, less harmful than all the severe side-effects induced by tramadol and morphine ([@B66]).

Overall, KTP derivatives do not trigger the major side-effects intrinsically associated with opioid receptor activation. This correlates with previous findings as direct binding of KTP amidated derivatives to opioid receptors is nearly absent ([@B63],[@B64]) similarly to the original KTP molecule ([@B60]). Taken together, our data indicates that KTP peptides and opioid drugs exhibit distinct mechanism of action. However, opioid pathways are indirectly involved in KTP peptides mode of action since naloxone decreases the analgesic efficacy of IbKTP-NH~2~ and completely abolishes KTP-NH~2~ analgesic activity ([@B63],[@B64]).

Therefore, the strong analgesic activity coupled with the absence of the major side-effects associated to opioids renders both KTP--NH~2~ and IbKTP--NH~2~ as potential advantageous alternatives over current opioids.

KTP Derivatives Beyond Analgesia
================================

As Antimicrobial Agents
-----------------------

Antimicrobial peptides represent a promising alternative to conventional antibiotics to fight resistant pathogens because development of resistance is not so effective. They are generally short amphiphilic cationic peptides with high affinity to negatively charged bacterial membranes. One possible mode of action, among others, is membrane disruption caused by peptide insertion into the bacterial membrane, short peptides having higher activity ([@B50]; [@B14]). [@B14] found that the tripeptide [L]{.smallcaps}-lysine-[L]{.smallcaps}-tyrosine-[L]{.smallcaps}-arginine (KYR) has antimicrobial activity. Since KTP (YR, net charge +1) does not have antimicrobial activity, the positive charge of lysine is of key importance. KTP (net charge: +1), KTP-NH~2~ (+2), IbKTP-NH~2~ (+1) and IbKTP (0) were tested against Gram-negative *Escherichia coli* (*E. coli*) and Gram-positive *Staphylococcus aureus* (*S. aureus*). ([@B67]). All derivatives were inactive against *E. coli* up to 100 μM but they were active against *S. aureus*, with the exception of KTP. Details of surface structure alteration induced by KTP derivatives (10 μM) in *S. aureus* were obtained by atomic force microscopy (AFM). KTP-NH~2~ and IbKTP-NH~2~ induced shape alterations, unlike KTP and IbKTP. Membrane blebbing and disruption were more evident for KTP-NH~2~. Ib-containing derivatives also interact with red blood cells (RBCs) outer monolayer changing the typical disk shape with uniform borders to spiky boundaries. This shape is known as echinocyte and is reversible. Regardless these changes all derivatives were virtually not toxic to RBCs ([@B67]).

Neuroprotective Potential in Cerebral Hypoperfusion Rat Model
-------------------------------------------------------------

In the last two decades, intensive efforts to develop disease-modifying drugs were made to counteract the progression of AD ([@B29]). Moreover, increasing attention has been dedicated to neuropeptides in the discovery of new drug targets for the treatment of nervous-system disorders ([@B36]). Actually, some neuropeptides are densely localized in cognition-related brain regions and play an important role in dementia-associated pathophysiological mechanisms ([@B11]).

Over the last decade, some authors hypothesized that KTP has neuromodulating and neuroprotective properties using animal models of cerebral resuscitation (after clinical death) ([@B53]) and of epilepsy (i.e., picrotoxin- or pentylenetetrazole-induced seizures) ([@B32]; [@B10]). In addition, there is consistent evidence about the protective role of NSAIDs, particularly Ib, against neurodegeneration and to reduce the risk of developing AD or Parkinson's ([@B7]; [@B16]; [@B98]). Hence, the potential of a drug candidate (namely KTP) comprising NSAID-based therapy to achieve a clinical benefit would be tremendous. In view of these facts and our recent clinical studies (see KTP as a Promising Biomarker in Alzheimer's Disease) the relevance of testing our improved KTP derivatives in dementia progression became obvious.

Therefore, KTP-NH~2~ and IbKTP-NH~2~ were recently studied for their ability in post-ischemia to ameliorate cognitive deficits induced by chronic brain hypoperfusion ([@B69]). Cerebrovascular hypoperfusion is known to be a prominent risk in the development of neurological dysfunction and dementia. In rats, permanent 2VO produces a lasting and reliable reduction of cerebral blood flow, which leads to a progressive neuropathological damage in the hippocampus (particularly its CA1 subfield), learning and memory impairments as it occurs in AD ([@B27]).

Our study included rats subjected to permanent global ischemia via 2VO-surgery (2VO-animals) and sham-operated animals (surgery without carotid artery ligation: control group). In the experimental paradigm, 2VO-animals were treated with KTP-NH~2~ (32.3 mg.kg^-1^) or IbKTP-NH~2~ (24.2 mg.kg^-1^) at weeks 2 and 5 post-surgery (single i.p. dose/day for 7 days) ([@B69]). From a therapeutic perspective, it was of interest to assess their effectiveness after the onset of ischemic injury. Selected doses of KTP-derivatives were based on our previous studies ([@B63],[@B64], [@B66]).

Following treatment regimen, motor and spatial memory functions were evaluated using the open-field test and two-trial recognition Y-maze task, respectively. Evidences support a direct correlation between cerebral hypoperfusion-induced memory impairments and damage in CA1 pyramidal neurons ([@B21]; [@B27]; [@B15]). So, we also evaluated hippocampal CA1 integrity through immunohistochemistry protocols ([@B69]).

Albeit ischemic injury can affect brain regions linked to motor function (i.e., cortex and neocortex), in our study there was no obvious signs of locomotion deficits in 2VO-operated animals ([@B69]), similar to what has been reported for this experimental model ([@B27]; [@B15]). Our findings clearly showed that both KTP-derivatives improved memory deficits of 2VO-animals and prevented CA1 neuronal injury ([@B69]). Detailed mechanisms underlying their neuroprotective properties are still unknown. However, IbKTP-NH~2~ was the more effective derivative in restoring normal memory function; the presence of NSAID ibuprofen may mitigate some neuroinflammatory events in 2VO-ischemic brain.

As Anti-Inflammatory Agents
---------------------------

Pain and inflammation are distinct physiological processes but they are frequently associated. Thus, the development of a single drug that could target pain and inflammation simultaneously would be ideal. We used an IVM approach to evaluate the pro- or anti-inflammatory effect of a topical application of KTP (96 μM), KTP-NH~2~ (96 μM), IbKTP (96 μM) and IbKTP-NH~2~ (96 μM) on the cremaster muscle using a rodent model of LPS-induced inflammation ([@B19]). We have previously shown that Ib moiety is a enhancer of KTP analgesic action ([@B64]). Accordingly, we expected that KTP could also be an enhancer of Ib anti-inflammatory action.

Our data showed that KTP and its analogs did not cause damage on microcirculation. In addition they decreased the number of rolling and adherent leukocytes induced by LPS. This result might be explained by the ability of KTP analogs to bind/perturb LPS micelles, as shown by isothermal titration calorimetry studies, probably contributing to LPS aggregation and subsequent elimination ([@B19]). Since KTP did not bind to LPS, the production of NO is the proposed anti-inflammatory mechanism. This is supported by the already discussed mechanism for KTP-induced analgesia that originates [L]{.smallcaps}-Arg, a well-known substrate for NOS that ultimately originates NO as product (see Mechanism of Action).

More recently, [D]{.smallcaps}-Tyr-[L]{.smallcaps}-Arg-NH~2~ (KTP-NH~2~-DL, 96 μM) also decreased the number of rolling leukocytes in a murine model of inflammation induced by LPS, but did not reveal a significant analgesic activity in the hot plate test ([@B57]). This KTP analog and others analyzed in the same study seem to have an action on the endothelium.

Concluding Remarks
==================

Pain is a huge social and economic problem. In the half last century, innovation in the field of analgesic drug has been scarce. An increased interest has been directed toward peptides as future pain-killers. KTP gathers an interesting and wide set of biological activities; among them, analgesia is by far the most studied. In order to make this peptide more attractive from a pharmacological perspective, several chemical modifications have been made to the original molecule. This strategy has been successful so far and new advantageous properties have emerged from these derivatives, creating a new class of molecules with an increased pharmacological value.
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2VO

:   bilateral common carotid artery occlusion

AMPs

:   antimicrobial peptides

Ib

:   ibuprofen

IVM

:   intravital microscopy

KTP

:   kyotorphin

KTPr

:   KTP receptor

KTP-NH~2~

:   KTP-amide

LPS

:   lipopolysaccharide

NO

:   nitric oxide

NOS

:   nitric oxide synthetase

PEPT2

:   peptide transporter 2

PLC

:   phospholipase C

*P*~R~

:   relative permeability

SP

:   substance P
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